Raphaël Wisniewski

Raphaël joined Andera Partners in 2001.

Since joining Andera he has worked on numerous investments, M&As and IPOs. Raphaël has in depth experience in all types of transactions gained both in banking and in Venture Capital.

He sits on the boards of Poxel, ReViral, MedDay Pharmaceuticals, Grey Wolf Therapeutics, Enyo Pharma, Dynacure, Artios, AM Pharma and Exciva. He was also a board member of Axonics Modulation Technologies, Novagali Pharma, Pangenetics, Chase Pharmaceuticals, Oncoethix and Vessix Vascular until their acquisition by large pharmaceutical or medical device companies.